![]() |
Essilorluxottica Société Anonyme (EL.PA) DCF -Bewertung
FR | Healthcare | Medical - Instruments & Supplies | EURONEXT
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
EssilorLuxottica SA (EL.PA) Bundle
Egal, ob Sie ein Investor oder Analyst sind, dieser DCF-Taschenrechner von Essilorluxottica Société Anonyme (ELPA) ist Ihr Anlaufwerk für eine genaue Bewertung. Es wird mit echten Daten von Essilorluxottica vorgeladen, sodass Sie die Prognosen anpassen und sofort die Auswirkungen beobachten können.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 14,429.0 | 19,820.0 | 24,494.0 | 25,395.0 | 26,508.0 | 31,081.0 | 36,442.9 | 42,729.8 | 50,101.4 | 58,744.6 |
Revenue Growth, % | 0 | 37.36 | 23.58 | 3.68 | 4.38 | 17.25 | 17.25 | 17.25 | 17.25 | 17.25 |
EBITDA | 2,609.0 | 4,706.0 | 6,103.0 | 6,181.0 | 6,554.0 | 7,198.7 | 8,440.6 | 9,896.7 | 11,604.0 | 13,605.9 |
EBITDA, % | 18.08 | 23.74 | 24.92 | 24.34 | 24.72 | 23.16 | 23.16 | 23.16 | 23.16 | 23.16 |
Depreciation | 2,156.0 | 2,387.0 | 2,921.0 | 2,947.0 | 3,098.0 | 3,866.6 | 4,533.7 | 5,315.8 | 6,232.9 | 7,308.1 |
Depreciation, % | 14.94 | 12.04 | 11.93 | 11.6 | 11.69 | 12.44 | 12.44 | 12.44 | 12.44 | 12.44 |
EBIT | 453.0 | 2,319.0 | 3,182.0 | 3,234.0 | 3,456.0 | 3,332.1 | 3,906.9 | 4,580.9 | 5,371.2 | 6,297.8 |
EBIT, % | 3.14 | 11.7 | 12.99 | 12.73 | 13.04 | 10.72 | 10.72 | 10.72 | 10.72 | 10.72 |
Total Cash | 8,926.0 | 3,335.0 | 1,989.0 | 2,559.0 | 2,251.0 | 6,550.4 | 7,680.5 | 9,005.5 | 10,559.0 | 12,380.6 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 2,507.0 | 2,389.0 | 2,732.0 | 2,969.0 | .0 | 3,249.4 | 3,810.0 | 4,467.3 | 5,237.9 | 6,141.5 |
Account Receivables, % | 17.37 | 12.05 | 11.15 | 11.69 | 0 | 10.45 | 10.45 | 10.45 | 10.45 | 10.45 |
Inventories | 1,992.0 | 2,527.0 | 2,910.0 | 2,750.0 | 3,152.0 | 3,801.5 | 4,457.4 | 5,226.3 | 6,127.9 | 7,185.1 |
Inventories, % | 13.81 | 12.75 | 11.88 | 10.83 | 11.89 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 |
Accounts Payable | 1,864.0 | 2,218.0 | 2,297.0 | 2,381.0 | 2,657.0 | 3,287.5 | 3,854.7 | 4,519.6 | 5,299.3 | 6,213.6 |
Accounts Payable, % | 12.92 | 11.19 | 9.38 | 9.38 | 10.02 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 |
Capital Expenditure | -650.0 | -1,030.0 | -1,572.0 | -1,531.0 | -1,522.0 | -1,733.7 | -2,032.8 | -2,383.5 | -2,794.6 | -3,276.8 |
Capital Expenditure, % | -4.5 | -5.2 | -6.42 | -6.03 | -5.74 | -5.58 | -5.58 | -5.58 | -5.58 | -5.58 |
Tax Rate, % | 28.32 | 28.32 | 28.32 | 28.32 | 28.32 | 28.32 | 28.32 | 28.32 | 28.32 | 28.32 |
EBITAT | 123.4 | 1,541.7 | 2,262.9 | 2,439.1 | 2,477.3 | 2,078.8 | 2,437.5 | 2,858.0 | 3,351.0 | 3,929.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -1,005.6 | 2,835.7 | 2,964.9 | 3,862.1 | 6,896.3 | 943.3 | 4,289.1 | 5,029.1 | 5,896.7 | 6,913.9 |
WACC, % | 8.04 | 8.19 | 8.21 | 8.23 | 8.21 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 |
PV UFCF | ||||||||||
SUM PV UFCF | 17,482.7 | |||||||||
Long Term Growth Rate, % | 3.00 | |||||||||
Free cash flow (T + 1) | 7,121 | |||||||||
Terminal Value | 137,543 | |||||||||
Present Terminal Value | 92,844 | |||||||||
Enterprise Value | 110,327 | |||||||||
Net Debt | 10,965 | |||||||||
Equity Value | 99,362 | |||||||||
Diluted Shares Outstanding, MM | 460 | |||||||||
Equity Value Per Share | 216.00 |
What You Will Receive
- Genuine EssilorLuxottica Data: Comprehensive financials – encompassing revenue to EBIT – derived from actual and projected metrics.
- Complete Customization: Modify all essential parameters (highlighted cells) such as WACC, growth %, and tax rates.
- Real-Time Valuation Adjustments: Automatic recalculations to assess the effects of changes on EssilorLuxottica’s fair value.
- Adaptable Excel Template: Designed for swift modifications, scenario analysis, and in-depth forecasts.
- Efficient and Reliable: Eliminate the need to build models from scratch while ensuring accuracy and flexibility.
Key Features
- Pre-Loaded Data: EssilorLuxottica’s historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: Observe EssilorLuxottica’s intrinsic value recalculating in real time.
- Clear Visual Outputs: Dashboard charts present valuation results and key metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.
How It Works
- Step 1: Download the prebuilt Excel template featuring EssilorLuxottica’s data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the key performance indicators.
- Step 3: Modify the forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view updated results, including EssilorLuxottica’s intrinsic value.
- Step 5: Make educated investment decisions or create reports based on the outputs.
Why Opt for This Calculator?
- All-in-One Tool: Features DCF, WACC, and financial ratio analyses bundled together.
- Adjustable Inputs: Modify the yellow-highlighted fields to explore different scenarios.
- In-Depth Analysis: Automatically computes EssilorLuxottica’s intrinsic value and Net Present Value.
- Integrated Data: Comes with historical and projected data for reliable starting points.
- High-Quality Standards: Perfect for financial analysts, investors, and business consultants.
Who Can Benefit from This Product?
- Investment Professionals: Develop comprehensive and trustworthy valuation models for analyzing portfolios.
- Corporate Finance Departments: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Financial Advisors: Deliver precise valuation insights for EssilorLuxottica's stock ([ELPA]).
- Students and Instructors: Utilize real-world data to enhance financial modeling skills in educational settings.
- Industry Enthusiasts: Gain insights into how companies like EssilorLuxottica are valued in the marketplace.
Contents of the Template
- Preloaded ELPA Data: Historical and projected financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Advanced spreadsheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells that allow users to modify revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis.
- Key Ratios: Metrics related to profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation outcomes and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.